UBS Upholds Buy Rating on ResMed, Citing Robust U.S. Market Position and Growth Prospects
UBS has reiterated its Buy recommendation for ResMed with a price target of $345, highlighting the company's sustained strength in the U.S. market and expected improvements in international sales. ResMed’s recent financial results surpassed revenue forecasts, although some analysts expressed caution due to competitive pressures and potential impact…